Comparative Pharmacology
Head-to-head clinical analysis: SUSTAIRE versus UNI DUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUSTAIRE versus UNI DUR.
SUSTAIRE vs UNI-DUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased cAMP production.
UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular cAMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.
50 mg orally twice daily
200-400 mg orally every 12 hours; maximum 800 mg daily.
None Documented
None Documented
Terminal elimination half-life of 8-12 hours in healthy adults; prolonged in renal impairment.
Terminal elimination half-life 24-36 hours; prolonged in renal impairment (up to 90 hours).
Primarily renal excretion (80-90% unchanged); minor biliary/fecal elimination (10-20%).
Primarily renal (70-80%) as unchanged drug and metabolites; 10-15% fecal.
Category C
Category C
Methylxanthine Bronchodilator
Methylxanthine Bronchodilator